Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nemiralisib - GlaxoSmithKline

Drug Profile

Nemiralisib - GlaxoSmithKline

Alternative Names: [14C]-GSK2269557; GSK 2269557; GSK 2269557 ELLIPTA DPI

Latest Information Update: 28 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiasthmatics; Indazoles; Indoles; Oxazoles; Piperazines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease; Immunodeficiency disorders
  • Phase I Bronchiectasis

Most Recent Events

  • 28 Nov 2019 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in Japan (Inhalation, Powder)
  • 10 Jan 2019 GlaxoSmithKline terminates phase II trial in Chronic obstructive pulmonary disease (In adults, In the elderly) in Argentina, Australia, Canada, France, Germany, Italy, Mexico, Netherlands, Poland, Romania, Russia, Scotland, South Korea, Spain, Sweden, United Kingdom, USA (EudraCT2017-001074-42) (NCT03345407)
  • 27 Jul 2018 GlaxoSmithKline initiates a phase IIa trial in Chronic obstructive pulmonary disease (In adults, In the elderly) in Spain (Inhalation) (EudraCT2017-004564-35)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top